Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2a plus ribavirin in chronic hepatitis C with compensated cirrhosis
jRCT2080220215Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection and Cirrhosis, sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on jRCT2080220215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220215.